Pancreatic Cancer Non Resectable clinical trials

Explore recruiting pancreatic cancer non resectable clinical trials.

Recruiting pancreatic cancer non resectable studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Cancer Non Resectable trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PHASE II study evaluating the benefit of Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic cancer" (IREC).

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients with Unresectable Locally Advanced Pancreatic Cancer

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER TO ASSESS SAFETY AND POTENTIAL EFFICACY OF DUAL CHECKPOINT INHIBITION IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL FOLLOWED BY IMMUNE-CHEMORADIATION.

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pancreatic Cancer Non Resectable trials by city

Pancreatic Cancer Non Resectable in Toronto Pancreatic Cancer Non Resectable in Vancouver Pancreatic Cancer Non Resectable in Montreal Pancreatic Cancer Non Resectable in Calgary Pancreatic Cancer Non Resectable in Edmonton Pancreatic Cancer Non Resectable in Ottawa Pancreatic Cancer Non Resectable in Winnipeg Pancreatic Cancer Non Resectable in Quebec City Pancreatic Cancer Non Resectable in Hamilton Pancreatic Cancer Non Resectable in Kitchener Pancreatic Cancer Non Resectable in London Pancreatic Cancer Non Resectable in Halifax Pancreatic Cancer Non Resectable in New York Pancreatic Cancer Non Resectable in Los Angeles Pancreatic Cancer Non Resectable in Chicago Pancreatic Cancer Non Resectable in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease